ALAMEDA, Calif.--(BUSINESS WIRE)--May 30, 2018--
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that Russell
Skibsted, Chief Financial Officer of BioTime, will be presenting at the 8th
Annual LD Micro Invitational Conference on Monday, June 4, 2018 at
1:30pm PT, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.
Mr. Skibsted will also be meeting with investors throughout the
conference. One-on-one meetings with Mr. Skibsted may be scheduled
through the LD Micro 1x1 desk or by contacting David Nakasone, Director
of Investor Relations at BioTime, at 510-871-4188 or email@example.com.
A webcast of Mr. Skibsted’s presentation at this conference will be
available at the Events
and Presentations section of the BioTime website.
The LD Micro conference will be held at the Luxe Sunset Bel Air Hotel,
will feature 230 companies in the small-cap / micro-cap space, and will
be attended by over 1,000 individuals.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on
degenerative diseases. Its clinical programs are based on two platform
technologies: cell replacement and cell/drug delivery. With its cell
replacement platform, BioTime is producing new cells and tissues with
its proprietary pluripotent cell technologies. These cells and tissues
are developed to replace those that are either rendered dysfunctional or
lost due to degenerative diseases or injuries. BioTime’s cell/drug
delivery programs are based upon its proprietary HyStem® cell
and drug delivery matrix technology. HyStem® was
designed, in part, to provide for the transfer, retention and/or
engraftment of cellular replacement therapies. BioTime’s lead cell
delivery clinical program is Renevia®, which consists of
HyStem® combined with the patient's own adipose (fat)
progenitor cells. Renevia® met its primary endpoint in an EU
pivotal clinical trial for the treatment of facial lipoatrophy in HIV
patients in 2017. BioTime has submitted Renevia® for
CE Mark approval in the EU. There were no device related serious adverse
events reported to date. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium
transplant therapy, which is in a Phase I/IIa multicenter clinical trial
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in developing countries. There were no unexpected
serious adverse events reported to date. BioTime also has significant
equity holdings in two publicly traded companies, Asterias
Biotherapeutics, Inc. (NYSE American: AST)
and OncoCyte Corporation (NYSE American: OCX), and a private
company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180530005338/en/
Source: BioTime, Inc.
David Nakasone, 510-871-4188